These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 1694156

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Male infertility caused by the chemotherapy of Hodgkin's disease: MOPP versus ABVD.
    Ragni G, Lombardi C, Santoro A, Bestetti O, Wyssling H.
    Acta Eur Fertil; 1983; 14(3):221-2. PubMed ID: 6199937
    [No Abstract] [Full Text] [Related]

  • 4. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP.
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [Abstract] [Full Text] [Related]

  • 5. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
    Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G, Lombardo F, Lenzi A, Gandini L.
    Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
    [Abstract] [Full Text] [Related]

  • 6. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA.
    J Clin Oncol; 2003 Feb 15; 21(4):607-14. PubMed ID: 12586796
    [Abstract] [Full Text] [Related]

  • 7. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood.
    van Beek RD, Smit M, van den Heuvel-Eibrink MM, de Jong FH, Hakvoort-Cammel FG, van den Bos C, van den Berg H, Weber RF, Pieters R, de Muinck Keizer-Schrama SM.
    Hum Reprod; 2007 Dec 15; 22(12):3215-22. PubMed ID: 17981817
    [Abstract] [Full Text] [Related]

  • 8. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.
    Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G.
    Eur J Cancer Clin Oncol; 1985 May 15; 21(5):601-5. PubMed ID: 2408897
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease.
    Brusamolino E, Lazzarino M, Morra E, Inverardi D, Merante S, Castelli G, Canevari A, Dornini G, Bernasconi C.
    Haematologica; 1989 May 15; 74(2):173-9. PubMed ID: 2473013
    [Abstract] [Full Text] [Related]

  • 11. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
    Bonadonna G, Santoro A, Bonfante V, Valagussa P.
    Cancer Treat Rep; 1982 Apr 15; 66(4):881-7. PubMed ID: 6176323
    [Abstract] [Full Text] [Related]

  • 12. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC.
    N Engl J Med; 1993 Apr 08; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract] [Full Text] [Related]

  • 13. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM, Colonna P.
    J Clin Oncol; 1998 Jun 08; 16(6):2283. PubMed ID: 9626234
    [No Abstract] [Full Text] [Related]

  • 14. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A, Ambrosetti A, Todeschini G, Cetto G, Perona G, Cellerino R.
    Cancer Treat Rep; 1984 Jun 08; 68(7-8):947-51. PubMed ID: 6204754
    [Abstract] [Full Text] [Related]

  • 15. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM.
    J Clin Oncol; 1998 Jan 08; 16(1):19-26. PubMed ID: 9440718
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
    Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P.
    Eur J Cancer; 2005 May 08; 41(7):998-1006. PubMed ID: 15862748
    [Abstract] [Full Text] [Related]

  • 18. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.
    van der Kaaij MA, Heutte N, Le Stang N, Raemaekers JM, Simons AH, Carde P, Noordijk EM, Fermé C, Thomas J, Eghbali H, Kluin-Nelemans HC, Henry-Amar M, European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group, Groupe d'Etude des Lymphomes de l'Adulte.
    J Clin Oncol; 2007 Jul 01; 25(19):2825-32. PubMed ID: 17515571
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.